中国新药杂志

治疗肺纤维化药物的评价与开发进展

PDF下载

邓龙 ¹^,²^,³ , 邹晓青 ¹ , 姜德建 ²

中国新药杂志 | 综述 2021,30(8): 712-717

收起

中国新药杂志 |综述 2021 , 30 (8) : 712 -717

治疗肺纤维化药物的评价与开发进展

全屏

邓龙¹^,²^,³, 邹晓青¹, 姜德建²

作者信息

¹湘潭大学化学学院，湘潭　411105

²湖南省药物安全评价研究中心，新药药效与安全性评价湖南省重点实验室，长沙　410331

³广东石油化工学院高新研究院，茂名　525000

通讯作者:

姜德建，男，博士生导师，研究员，主要从事药物药理学及毒理学研究。E-mail：jiangdejian@hnse.org。

作者简介:

邓龙，女，硕士研究生，主要从事呼吸系统药理毒理研究。E-mail：denglong@hnse.org。

Progress in evaluation and development of drugs for treatment of pulmonary fibrosis

Long DENG¹^,²^,³, Xiao-qing ZOU¹, De-jian JIANG²

Affiliations

¹College of Chemistry, Xiangtan University, Xiangtan 411105, China

²Hunan Research Center for Safety Evaluation of Drugs, Hunan Key Laboratory of Pharmacodynamics and Safety Evaluation of New Drugs, Changsha 410331, China

³High Tech Research Institute, Guangdong University of Petrochemical Technology, Maoming 525000, China

出版时间: 2021-04-30

文章导航

摘要

收起

肺纤维化是一大类肺疾病的终末期改变，是肺脏疾病致死的主要原因之一。本文综述了近年来肺纤维化发病机制、动物疾病模型、在研药物与药物作用新靶点的研究进展，旨在为治疗肺纤维化药物开发提供新思路。

关键词

肺纤维化 / 动物模型 / 药物开发

Abstract

收起

Pulmonary fibrosis (PF) is an advancing and fatal lung disease with increasing incidence and prevalence, which is one of the leading causes of death from lung diseases. This article summarizes the recent advances in disease pathogenesis, animal models, drugs under investigation and therapeutic targets, aiming to provide new ideas for developing drugs to treat pulmonary fibrosis.

Key words

pulmonary fibrosis / animal models / drug development

引用本文

邓龙, 邹晓青, 姜德建. 治疗肺纤维化药物的评价与开发进展. 中国新药杂志, 2021 , 30 (8) : 712 -717 .

Long DENG, Xiao-qing ZOU, De-jian JIANG. Progress in evaluation and development of drugs for treatment of pulmonary fibrosis[J]. Chinese Journal of New Drugs, 2021 , 30 (8) : 712 -717 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

HOPKINS RB, BURKE N, FELL C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada[J]. Eur Respir J, 2016, 48(1): 187-195.

[2]

HUTCHINSON J, FOGARTY A, HUBBARD R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review[J]. Eur Respir J, 2015, 46(3): 795-806.

[3]

王栋, 颜培正, 陈海红, 等. 自噬调节与特发性肺纤维化药物治疗研究进展[J]. 中国现代应用药学, 2021, 38(6): 759-761.

[4]

范碧君, 蒋捍东. 2015版特发性肺纤维化治疗指南解读[J]. 世界临床药物, 2016, 37(7): 453-456.

[5]

RAGHU G, COLLARD HR, EGAN JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183(6): 788-824.

[6]

RAIMUNDO K, CHANG E, BRODER MS, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study[J]. BMC Pulm Med, 2016, 16: 2.

[7]

陈海红, 杨军, 陈召慧, 等. 抗肺纤维化药物尼达尼布的研究进展[J]. 中国新药杂志, 2020, 29(10): 1131-1135.

[8]

MEYER KC, NATHAN SD. Idiopathic pulmonary fibrosis[M]. Totowa, NJ: Humana Press, 2014.

[9]

PARKER MW, ROSSI D, PETERSON M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop[J]. J Clin Invest, 2014, 124(4): 1622-1635.

[10]

耿艳艳, 周植星, 胡倩倩, 等. 特发性肺纤维化治疗靶点及药物研究进展[J]. 中国新药杂志, 2015, 24(1): 46-51.

[11]

KAUR A, MATHAI SK, SCHWARTZ DA. Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment[J]. Front Med, 2017, 4: 154.

[12]

ZANK DC, BUENO M, MORA AL, et al. Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics[J]. Front Med (Lausanne), 2018, 5: 10.

[13]

GLASSER SW, HAGOOD JS, WONG S, et al. Mechanisms of lung fibrosis resolution[J]. Am J Pathol, 2016, 186(5): 1066-1077.

[14]

DESAI TJ, BROWNFIELD DG, KRASNOW MA. Alveolar progenitor and stem cells in lung development, renewal and cancer[J]. Nature, 2014, 507(7491): 190-194.

[15]

NAIKAWADI RP, DISAYABUTR S, MALLAVIA B, et al. Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis[J]. JCI Insight, 2016, 1(14): e86704.

[16]

LIANG J, ZHANG Y, XIE T, et al. Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice[J]. Nat Med, 2016, 22(11): 1285-1293.

[17]

WOLTERS PJ, COLLARD HR, JONES KD. Pathogenesis of idiopathic pulmonary fibrosis[J]. Annu Rev Pathol, 2014, 9: 157-179.

[18]

MARTINEZ FJ, COLLARD HR, PARDO A, et al. Idiopathic pulmonary fibrosis[J]. Nat Rev Dis Primers, 2017, 3: 17074.

[19]

HUNG C, LINN G, CHOW YH, et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2013, 188(7): 820-830.

[20]

CHEN HP, QU J, HUANG XW, et al. Mechanosensing by the α6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis[J]. Nat Commun, 2016, 7: 12564.

[21]

TSCHUMPERLIN DJ. Matrix, mesenchyme, and mechanotransduction[J]. Ann Am Thorac Soc, 2015, 12(Suppl 1): S24-S29.

[22]

ZHOU Y, HUANG XW, HECKER L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis[J]. J Clin Invest, 2013, 123(3): 1096-1108.

[23]

MOORE BB, MURRAY L, DAS A, et al. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis[J]. Am J Respir Cell Mol Biol, 2006, 35(2): 175-181.

[24]

B MOORE B, LAWSON WE, OURY TD, et al. Animal models of fibrotic lung disease[J]. Am J Respir Cell Mol Biol, 2013, 49(2): 167-179.

[25]

EPPERLY MW, GUO HL, GRETTON JE, et al. Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis[J]. Am J Respir Cell Mol Biol, 2003, 29(2): 213-224.

[26]

KATZENSTEIN ALA, MUKHOPADHYAY S, MYERS JL. Erratum to “Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases”[J]. Hum Pathol, 2008, 39(11): 1562-1581.

[27]

LEE CG, CHO SJ, KANG MJ, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis[J]. J Exp Med, 2004, 200(3): 377-389.

[28]

冯凡超. 陈皮碱性提取物通过抑制肺成纤维细胞衰老抗肺纤维化作用机制研究[D]. 南京: 南京中医药大学, 2019.

[29]

刘青. 辛伐他汀对博莱霉素诱导的大鼠肺纤维化及肺组织PTEN、TGF-β1和α-SMA表达的影响[D]. 衡阳: 南华大学, 2014.

[30]

于小林, 张晓梅, 张艳霞, 等. 肺纤维化动物模型研究近况[J]. 河南中医, 2017, 37(11): 1926-1928.

[31]

ALAGHA K, SECQ V, PAHUS L, et al. We should prohibit warfarin in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2015, 191(8): 958-960.

[32]

RAGHU G, RICHELDI L, CRESTANI B, et al. Safety and efficacy of SAR156597 in idiopathic pulmonary fibrosis (IPF): a phase 2, randomized, double-blind, placebo-controlled study, A93. ILD: CLINICAL TRIALS[J]. Am Thoracic Society, 2018: A2441-A2441.

[33]

BLACK M, MILEWSKI D, LE TE, et al. FOXF1 inhibits pulmonary fibrosis by preventing CDH2-CDH11 cadherin switch in myofibroblasts[J]. Cell Rep, 2018, 23(2): 442-458.

[34]

PENKE LR, SPETH JM, DOMMETI VL, et al. FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis[J]. J Clin Invest, 2018, 128(6): 2389-2405.

[35]

GOMES AR, ZHAO F, LAM EW. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance[J]. Chin J Cancer, 2013, 32(7): 365-370.

[36]

IM J, LAWRENCE J, SEELIG D, et al. FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death[J]. Cell Death Dis, 2018, 9(6): 584.

[37]

BALLI D, USTIYAN V, ZHANG Y, et al. Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition[J]. EMBO J, 2013, 32(2): 231-244.

[38]

WILM B, MUÑOZ-CHAPULI R. The role of WT1 in embryonic development and normal organ homeostasis[J]. Methods Mol Biol, 2016, 1467: 23-39.

[39]

LUZINA IG, SALCEDO MV, ROJAS-PEÑA ML, et al. Transcriptomic evidence of immune activation in macroscopically normal-appearing and scarred lung tissues in idiopathic pulmonary fibrosis[J]. Cell Immunol, 2018, 325: 1-13.

[40]

SONTAKE V, KASAM RK, SINNER D, et al. Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease[J]. JCI Insight, 2018, 3(16): e121252.

[41]

BELLAYE PS, BURGY O, CAUSSE S, et al. Heat shock proteins in fibrosis and wound healing: good or evil?[J]. Pharmacol Ther, 2014, 143(2): 119-132.

[42]

BELLAYE PS, SHIMBORI C, YANAGIHARA T, et al. Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis[J]. Eur Respir J, 2018, 51(2): 1700386.

[43]

SONTAKE V, WANG Y, KASAM RK, et al. Hsp90 regulation of fibroblast activation in pulmonary fibrosis[J]. JCI Insight, 2017, 2(4): e91454.

[44]

DONG H, LUO L, ZOU M, et al. Blockade of extracellular heat shock protein 90α by 1G6-D7 attenuates pulmonary fibrosis through inhibiting ERK signaling[J]. Am J Physiol Lung Cell Mol Physiol, 2017, 313(6): L1006-L1015.

[45]

SIBINSKA Z, TIAN X, KORFEI M, et al. Amplified canonical transforming growth factor-β signalling via heat shock protein 90 in pulmonary fibrosis[J]. Eur Respir J, 2017, 49(2): 1501941.

[46]

TOMCIK M, ZERR P, PITKOWSKI J, et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis[J]. Ann Rheum Dis, 2014, 73(6): 1215-1222.

2021年第30卷第8期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-04-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-09-29

基金

作者信息

¹湘潭大学化学学院，湘潭　411105

²湖南省药物安全评价研究中心，新药药效与安全性评价湖南省重点实验室，长沙　410331

³广东石油化工学院高新研究院，茂名　525000

通讯作者:

姜德建，男，博士生导师，研究员，主要从事药物药理学及毒理学研究。E-mail：jiangdejian@hnse.org。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322245663388188858

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT